MRNA
MRNA
Below 50DMA, weak 3m, high volatility
Price
Price at analysis
$46.65
The case
● Bull — what supports it
Above 200DMA, pipeline optionality (oncology/RSV); deeply de-rated.
● Bear — what refutes it
Below 50DMA, -16.7% 3m, 6.3% ATR, declining COVID revenue, binary pipeline risk.
What would change our mind
Drake commits in advance to what would prove this call wrong — falsifiers, not hindsight.
- Reclaim 50DMA with pipeline catalyst.
The verdict
Sector analyst (Drake panel)–neutral
conviction 0.50
- Below 50DMA, weak 3m, high volatility
- Revenue cliff + binary pipeline
Risks: Below 50DMA, -16.7% 3m, 6.3% ATR, declining COVID revenue, binary pipeline risk.
Forward-only: this call is graded against the future, on its resolution date — never backfilled. This run carries a single synthesized panel verdict; multi-specialist runs list each view above.